ArticleBMC infectious diseases2022

Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.

Anlei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.